세계의 특발성 폐섬유증(IPF) 시장(2025-2029년)

The idiopathic pulmonary fibrosis (IPF) market is forecasted to grow by USD 1605.5 million during 2024-2029, accelerating at a CAGR of 6.9% during the forecast period. The report on the idiopathic pulmonary fibrosis (IPF) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of respiratory diseases, growing geriatric population, and increase in number of smokers.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's idiopathic pulmonary fibrosis (IPF) market is segmented as below:

By Route Of Administration

• Oral
• Parenteral

By Drug Class

• Systemic corticosteroids
• Immunosuppressants
• Tyrosine kinase inhibitors
• Anti-fibrotic agents

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the increase in drug pipeline for IPF as one of the prime reasons driving the idiopathic pulmonary fibrosis (IPF) market growth during the next few years. Also, development of novel drugs for treatment of IPF and emergence of new patterns of IPF will lead to sizable demand in the market.

The report on the idiopathic pulmonary fibrosis (IPF) market covers the following areas:

• Idiopathic Pulmonary Fibrosis (IPF) Market sizing
• Idiopathic Pulmonary Fibrosis (IPF) Market forecast
• Idiopathic Pulmonary Fibrosis (IPF) Market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading idiopathic pulmonary fibrosis (IPF) market vendors that include Alembic Pharmaceuticals Ltd., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celix Pharma Ltd., Cipla Inc., Daewoong Pharmaceutical Co. Ltd., F. Hoffmann La Roche Ltd., FibroGen Inc., Galapagos NV, Galecto Inc., GNI Group Ltd., Horizon Therapeutics PLC, Intas Pharmaceuticals Ltd., Jubilant Pharmova Ltd., MediciNova Inc., Merck and Co. Inc., Mission Therapeutics, Novartis AG, SHIONOGI Co. Ltd., and United Therapeutics Corp.. Also, the idiopathic pulmonary fibrosis (IPF) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market By Geographical Landscape
  • Executive Summary - Chart on Market Segmentation by Route of Administration
  • Executive Summary - Chart on Market Segmentation by Drug Class
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
  • Overview on criticality of inputs and factors of differentiation
• 2.3 Factors of disruption
  • Overview on factors of disruption
• 2.4 Impact of drivers and challenges
  • Impact of drivers and challenges in 2024 and 2029

3 Market Landscape

• 3.1 Market ecosystem
  • Parent Market
  • Data Table on - Parent Market
• 3.2 Market characteristics
  • Market characteristics analysis
• 3.3 Value chain analysis
  • Value chain analysis

4 Market Sizing

• 4.1 Market definition
  • Offerings of companies included in the market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2024
• 4.4 Market outlook: Forecast for 2024-2029
  • Chart on Global - Market size and forecast 2024-2029 ($ million)
  • Data Table on Global - Market size and forecast 2024-2029 ($ million)
  • Chart on Global Market: Year-over-year growth 2024-2029 (%)
  • Data Table on Global Market: Year-over-year growth 2024-2029 (%)

5 Historic Market Size

• 5.1 Global Idiopathic Pulmonary Fibrosis (IPF) Market 2019 - 2023
  • Historic Market Size - Data Table on Global Idiopathic Pulmonary Fibrosis (IPF) Market 2019 - 2023 ($ million)
• 5.2 Route of Administration segment analysis 2019 - 2023
  • Historic Market Size - Route of Administration Segment 2019 - 2023 ($ million)
• 5.3 Drug Class segment analysis 2019 - 2023
  • Historic Market Size - Drug Class Segment 2019 - 2023 ($ million)
• 5.4 Distribution Channel segment analysis 2019 - 2023
  • Historic Market Size - Distribution Channel Segment 2019 - 2023 ($ million)
• 5.5 Geography segment analysis 2019 - 2023
  • Historic Market Size - Geography Segment 2019 - 2023 ($ million)
• 5.6 Country segment analysis 2019 - 2023
  • Historic Market Size - Country Segment 2019 - 2023 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on Global Idiopathic Pulmonary Fibrosis (IPF) Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2024 and 2029
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2024 and 2029
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2024 and 2029
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2024 and 2029
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2024 and 2029
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2024 and 2029
• 7.7 Market condition
  • Chart on Market condition - Five forces 2024 and 2029

8 Market Segmentation by Route of Administration

• 8.1 Market segments
  • Chart on Route of Administration - Market share 2024-2029 (%)
  • Data Table on Route of Administration - Market share 2024-2029 (%)
• 8.2 Comparison by Route of Administration
  • Chart on Comparison by Route of Administration
  • Data Table on Comparison by Route of Administration
• 8.3 Oral - Market size and forecast 2024-2029
  • Chart on Oral - Market size and forecast 2024-2029 ($ million)
  • Data Table on Oral - Market size and forecast 2024-2029 ($ million)
  • Chart on Oral - Year-over-year growth 2024-2029 (%)
  • Data Table on Oral - Year-over-year growth 2024-2029 (%)
• 8.4 Parenteral - Market size and forecast 2024-2029
  • Chart on Parenteral - Market size and forecast 2024-2029 ($ million)
  • Data Table on Parenteral - Market size and forecast 2024-2029 ($ million)
  • Chart on Parenteral - Year-over-year growth 2024-2029 (%)
  • Data Table on Parenteral - Year-over-year growth 2024-2029 (%)
• 8.5 Market opportunity by Route of Administration
  • Market opportunity by Route of Administration ($ million)
  • Data Table on Market opportunity by Route of Administration ($ million)

9 Market Segmentation by Drug Class

• 9.1 Market segments
  • Chart on Drug Class - Market share 2024-2029 (%)
  • Data Table on Drug Class - Market share 2024-2029 (%)
• 9.2 Comparison by Drug Class
  • Chart on Comparison by Drug Class
  • Data Table on Comparison by Drug Class
• 9.3 Systemic corticosteroids - Market size and forecast 2024-2029
  • Chart on Systemic corticosteroids - Market size and forecast 2024-2029 ($ million)
  • Data Table on Systemic corticosteroids - Market size and forecast 2024-2029 ($ million)
  • Chart on Systemic corticosteroids - Year-over-year growth 2024-2029 (%)
  • Data Table on Systemic corticosteroids - Year-over-year growth 2024-2029 (%)
• 9.4 Immunosuppressants - Market size and forecast 2024-2029
  • Chart on Immunosuppressants - Market size and forecast 2024-2029 ($ million)
  • Data Table on Immunosuppressants - Market size and forecast 2024-2029 ($ million)
  • Chart on Immunosuppressants - Year-over-year growth 2024-2029 (%)
  • Data Table on Immunosuppressants - Year-over-year growth 2024-2029 (%)
• 9.5 Tyrosine kinase inhibitors - Market size and forecast 2024-2029
  • Chart on Tyrosine kinase inhibitors - Market size and forecast 2024-2029 ($ million)
  • Data Table on Tyrosine kinase inhibitors - Market size and forecast 2024-2029 ($ million)
  • Chart on Tyrosine kinase inhibitors - Year-over-year growth 2024-2029 (%)
  • Data Table on Tyrosine kinase inhibitors - Year-over-year growth 2024-2029 (%)
• 9.6 Anti-fibrotic agents - Market size and forecast 2024-2029
  • Chart on Anti-fibrotic agents - Market size and forecast 2024-2029 ($ million)
  • Data Table on Anti-fibrotic agents - Market size and forecast 2024-2029 ($ million)
  • Chart on Anti-fibrotic agents - Year-over-year growth 2024-2029 (%)
  • Data Table on Anti-fibrotic agents - Year-over-year growth 2024-2029 (%)
• 9.7 Market opportunity by Drug Class
  • Market opportunity by Drug Class ($ million)
  • Data Table on Market opportunity by Drug Class ($ million)

10 Market Segmentation by Distribution Channel

• 10.1 Market segments
  • Chart on Distribution Channel - Market share 2024-2029 (%)
  • Data Table on Distribution Channel - Market share 2024-2029 (%)
• 10.2 Comparison by Distribution Channel
  • Chart on Comparison by Distribution Channel
  • Data Table on Comparison by Distribution Channel
• 10.3 Hospital pharmacies - Market size and forecast 2024-2029
  • Chart on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
  • Data Table on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
  • Chart on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
  • Data Table on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
• 10.4 Retail pharmacies - Market size and forecast 2024-2029
  • Chart on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
  • Data Table on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
  • Chart on Retail pharmacies - Year-over-year growth 2024-2029 (%)
  • Data Table on Retail pharmacies - Year-over-year growth 2024-2029 (%)
• 10.5 Online pharmacies - Market size and forecast 2024-2029
  • Chart on Online pharmacies - Market size and forecast 2024-2029 ($ million)
  • Data Table on Online pharmacies - Market size and forecast 2024-2029 ($ million)
  • Chart on Online pharmacies - Year-over-year growth 2024-2029 (%)
  • Data Table on Online pharmacies - Year-over-year growth 2024-2029 (%)
• 10.6 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ million)
  • Data Table on Market opportunity by Distribution Channel ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
  • Chart on Market share By Geographical Landscape 2024-2029 (%)
  • Data Table on Market share By Geographical Landscape 2024-2029 (%)
• 12.2 Geographic comparison
  • Chart on Geographic comparison
  • Data Table on Geographic comparison
• 12.3 North America - Market size and forecast 2024-2029
  • Chart on North America - Market size and forecast 2024-2029 ($ million)
  • Data Table on North America - Market size and forecast 2024-2029 ($ million)
  • Chart on North America - Year-over-year growth 2024-2029 (%)
  • Data Table on North America - Year-over-year growth 2024-2029 (%)
• 12.4 Europe - Market size and forecast 2024-2029
  • Chart on Europe - Market size and forecast 2024-2029 ($ million)
  • Data Table on Europe - Market size and forecast 2024-2029 ($ million)
  • Chart on Europe - Year-over-year growth 2024-2029 (%)
  • Data Table on Europe - Year-over-year growth 2024-2029 (%)
• 12.5 Asia - Market size and forecast 2024-2029
  • Chart on Asia - Market size and forecast 2024-2029 ($ million)
  • Data Table on Asia - Market size and forecast 2024-2029 ($ million)
  • Chart on Asia - Year-over-year growth 2024-2029 (%)
  • Data Table on Asia - Year-over-year growth 2024-2029 (%)
• 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
  • Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
  • Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
  • Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
  • Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
• 12.7 US - Market size and forecast 2024-2029
  • Chart on US - Market size and forecast 2024-2029 ($ million)
  • Data Table on US - Market size and forecast 2024-2029 ($ million)
  • Chart on US - Year-over-year growth 2024-2029 (%)
  • Data Table on US - Year-over-year growth 2024-2029 (%)
• 12.8 Canada - Market size and forecast 2024-2029
  • Chart on Canada - Market size and forecast 2024-2029 ($ million)
  • Data Table on Canada - Market size and forecast 2024-2029 ($ million)
  • Chart on Canada - Year-over-year growth 2024-2029 (%)
  • Data Table on Canada - Year-over-year growth 2024-2029 (%)
• 12.9 China - Market size and forecast 2024-2029
  • Chart on China - Market size and forecast 2024-2029 ($ million)
  • Data Table on China - Market size and forecast 2024-2029 ($ million)
  • Chart on China - Year-over-year growth 2024-2029 (%)
  • Data Table on China - Year-over-year growth 2024-2029 (%)
• 12.10 Japan - Market size and forecast 2024-2029
  • Chart on Japan - Market size and forecast 2024-2029 ($ million)
  • Data Table on Japan - Market size and forecast 2024-2029 ($ million)
  • Chart on Japan - Year-over-year growth 2024-2029 (%)
  • Data Table on Japan - Year-over-year growth 2024-2029 (%)
• 12.11 Germany - Market size and forecast 2024-2029
  • Chart on Germany - Market size and forecast 2024-2029 ($ million)
  • Data Table on Germany - Market size and forecast 2024-2029 ($ million)
  • Chart on Germany - Year-over-year growth 2024-2029 (%)
  • Data Table on Germany - Year-over-year growth 2024-2029 (%)
• 12.12 UK - Market size and forecast 2024-2029
  • Chart on UK - Market size and forecast 2024-2029 ($ million)
  • Data Table on UK - Market size and forecast 2024-2029 ($ million)
  • Chart on UK - Year-over-year growth 2024-2029 (%)
  • Data Table on UK - Year-over-year growth 2024-2029 (%)
• 12.13 Mexico - Market size and forecast 2024-2029
  • Chart on Mexico - Market size and forecast 2024-2029 ($ million)
  • Data Table on Mexico - Market size and forecast 2024-2029 ($ million)
  • Chart on Mexico - Year-over-year growth 2024-2029 (%)
  • Data Table on Mexico - Year-over-year growth 2024-2029 (%)
• 12.14 France - Market size and forecast 2024-2029
  • Chart on France - Market size and forecast 2024-2029 ($ million)
  • Data Table on France - Market size and forecast 2024-2029 ($ million)
  • Chart on France - Year-over-year growth 2024-2029 (%)
  • Data Table on France - Year-over-year growth 2024-2029 (%)
• 12.15 Brazil - Market size and forecast 2024-2029
  • Chart on Brazil - Market size and forecast 2024-2029 ($ million)
  • Data Table on Brazil - Market size and forecast 2024-2029 ($ million)
  • Chart on Brazil - Year-over-year growth 2024-2029 (%)
  • Data Table on Brazil - Year-over-year growth 2024-2029 (%)
• 12.16 Italy - Market size and forecast 2024-2029
  • Chart on Italy - Market size and forecast 2024-2029 ($ million)
  • Data Table on Italy - Market size and forecast 2024-2029 ($ million)
  • Chart on Italy - Year-over-year growth 2024-2029 (%)
  • Data Table on Italy - Year-over-year growth 2024-2029 (%)
• 12.17 Market opportunity By Geographical Landscape
  • Market opportunity By Geographical Landscape ($ million)
  • Data Tables on Market opportunity By Geographical Landscape ($ million)

13 Drivers, Challenges, and Opportunity/Restraints

• 13.1 Market drivers
• 13.2 Market challenges
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2024 and 2029
• 13.4 Market opportunities/restraints

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Product / Service
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • SWOT
• 15.5 Boehringer Ingelheim International GmbH
  • Boehringer Ingelheim International GmbH - Overview
  • Boehringer Ingelheim International GmbH - Product / Service
  • Boehringer Ingelheim International GmbH - Key news
  • Boehringer Ingelheim International GmbH - Key offerings
  • SWOT
• 15.6 Bristol Myers Squibb Co.
  • Bristol Myers Squibb Co. - Overview
  • Bristol Myers Squibb Co. - Product / Service
  • Bristol Myers Squibb Co. - Key news
  • Bristol Myers Squibb Co. - Key offerings
  • SWOT
• 15.7 Celix Pharma Ltd.
  • Celix Pharma Ltd. - Overview
  • Celix Pharma Ltd. - Product / Service
  • Celix Pharma Ltd. - Key offerings
  • SWOT
• 15.8 Cipla Inc.
  • Cipla Inc. - Overview
  • Cipla Inc. - Business segments
  • Cipla Inc. - Key news
  • Cipla Inc. - Key offerings
  • Cipla Inc. - Segment focus
  • SWOT
• 15.9 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
• 15.10 FibroGen Inc.
  • FibroGen Inc. - Overview
  • FibroGen Inc. - Product / Service
  • FibroGen Inc. - Key offerings
  • SWOT
• 15.11 Galapagos NV
  • Galapagos NV - Overview
  • Galapagos NV - Product / Service
  • Galapagos NV - Key offerings
  • SWOT
• 15.12 GNI Group Ltd.
  • GNI Group Ltd. - Overview
  • GNI Group Ltd. - Product / Service
  • GNI Group Ltd. - Key offerings
  • SWOT
• 15.13 Horizon Therapeutics Plc
  • Horizon Therapeutics Plc - Overview
  • Horizon Therapeutics Plc - Product / Service
  • Horizon Therapeutics Plc - Key offerings
  • SWOT
• 15.14 Jubilant Pharmova Ltd.
  • Jubilant Pharmova Ltd. - Overview
  • Jubilant Pharmova Ltd. - Business segments
  • Jubilant Pharmova Ltd. - Key news
  • Jubilant Pharmova Ltd. - Key offerings
  • Jubilant Pharmova Ltd. - Segment focus
  • SWOT
• 15.15 MediciNova Inc.
  • MediciNova Inc. - Overview
  • MediciNova Inc. - Product / Service
  • MediciNova Inc. - Key offerings
  • SWOT
• 15.16 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 15.17 SHIONOGI Co. Ltd.
  • SHIONOGI Co. Ltd. - Overview
  • SHIONOGI Co. Ltd. - Product / Service
  • SHIONOGI Co. Ltd. - Key offerings
  • SWOT
• 15.18 United Therapeutics Corp.
  • United Therapeutics Corp. - Overview
  • United Therapeutics Corp. - Product / Service
  • United Therapeutics Corp. - Key offerings
  • SWOT

16 Appendix

• 16.1 Scope of the report
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations